

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Remarks

Response to Restriction Requirement

In the Office Action mailed April 19, 2006, the claims were divided into 3 groups: Group I, claims 1-29, drawn to an orally administrable composition; Group II, claims 30-31, drawn to a method of manufacturing an abuse resistant pharmaceutical compositions; and Group III, claim 32, drawn to a method of administering an abuse resistant pharmaceutical composition.

In response, applicants elect Group I, claims 1-29, without traverse. Claims 14 and 30-32 have been canceled. Applicants reserve all rights in these claims to file divisional and continuation patent applications.

The Office Action also required election of a species from among (a) a composition comprising a lipophilic derivative; and (b) a water-insoluble, preferably lipophilic, formulation in claim 1. In response, applicants elect for examination (a) a composition comprising a lipophilic derivative, without traverse. Claims 1-13, and 15-29 read on the elected species.

U.S.S.N. 10/614,866

Filed: July 7, 2003

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Favorable consideration of claims 1-13, and 15-29 is respectfully solicited.

Respectfully submitted,

/Patrea L. Pabst/

Patrea L. Pabst

Reg. No. 31,284

Date: May 9, 2006

PABST PATENT GROUP, LLP

400 Colony Square, Suite 1200

1201 Peachtree Street

Atlanta, Georgia 30361

(404) 879-2151

(404) 879-2160 (fax)